Amphastar, a specialty pharmaceutical company, agreed to acquire a 26% stake in Amphastar Nanjing Pharmaceuticals, a Chinese subsidiary of Amphastar. Financial terms were not disclosed. "We believe that the restructuring of ANP is the most effective way for us to continue expanding globally while maintaining control of our important API manufacturing capabilities and eliminating expenses for areas unrelated to Amphastar’s pipeline products. We expect the transaction to be accretive to Amphastar’s EPS by approximately $0.03 per share in 2021 and $0.12 per share in 2022," Jack Zhang, Amphastar CEO.